Company: LGNZZ
Filing Date: 2025-08-14
Form Type: 8-K
Source: 0001193125-25-180841
Chunk: 8

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-14
Form: 8-K
Item: Item 8.01
Chunk 8
---
Item 8.01 Other Events.

On August 11, 2025, the Company issued a press release announcing the pricing of its offering of $400.0 million aggregate principal amount of Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. A copy of the press release announcing the pricing of the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On August 14, 2025, the Company issued a press release announcing the closing of its offering of $460.0 million aggregate principal amount of Notes, including the exercise in full of the initial purchasers’ option to purchase up to an additional $60.0 million aggregate principal amount of Notes, in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. A copy of the press release announcing the closing of the offering is attached hereto as Exhibit 99.2 and is incorporated herein by reference.